Coave Therapeutics SA

Coave Therapeutics SA, based in France, specializes in gene therapies for rare ocular and central nervous system diseases, utilizing their proprietary ALIGATER™ platform to enhance treatment delivery and efficacy. Founded in 2014 in Paris, France, Coave Therapeutics SA develops innovative gene therapies targeting rare diseases. The leadership team includes CEO Christine Placet, with Rodolphe Clerval also playing a key role. The company has successfully raised EUR 32.

000 mn in Series A funding co-led by Novo Holdings AS and Bpifrance Investissement, with participation from several other investors. Coave has completed 5 deals, with the most recent occurring on December 10, 2024, marking a significant step in their growth trajectory. Coave Therapeutics specializes in advanced gene therapies targeting rare ocular and central nervous system (CNS) diseases. Their primary focus is on their proprietary ALIGATER™ platform, which develops conjugated adeno-associated virus (coAAV) vectors for enhanced gene therapy delivery.

Their treatment offerings address serious conditions, including amyotrophic lateral sclerosis (ALS) and inherited retinal dystrophies such as retinitis pigmentosa, primarily aimed at healthcare providers and clinical research institutions in North America and Europe. Coave Therapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions. Their revenue model includes agreements for research and development milestones, licensing deals, and co-development partnerships, sharing risks and rewards in product development. Their flagship products, CTx-TFEB and CTx-PDE6b, are expected to drive future revenue through potential commercialization.

Revenue streams may include upfront payments, equity investments, and royalties from successful product launches, with the company reporting an EBITDA of EUR -4,568,703 for the most recent year in 2017. In December 2024, Coave Therapeutics SA raised EUR 32. 000 mn in Series A funding to accelerate its research and development of genetic medicine. This strategic funding, led by new investors, will support the launch of new products and expansion into new markets.

Coave aims to enhance its offerings and reach a broader patient base as part of its growth strategy.